Hayden is an associate editor for The American Journal of Managed Care® (AJMC®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Julie Reed Previews Biosimilar Session at Asembia 2023
April 25th 2023At Asembia 2023, there will be a call to action for participants to adjust their current business models and advocate for access to biosimilars with lower list costs, explained Julie Reed, executive director of the Biosimilars Forum.
T1D Plus Psychiatric Disorders May Influence Educational Outcomes
April 20th 2023Although children with type 1 diabetes (T1D) are slightly more likely to experience long-term educational underachievement than their peers without T1D, those who also have a psychiatric disorder have significantly lower odds of achieving educational milestones.
People With HIV at Much Higher Risk of Depression, Suicide
April 19th 2023In the first 2 years after receiving an HIV diagnosis, people with HIV were about 3 times more likely to develop depression, use antidepressants, and undergo electroconvulsive therapy—and 10 times more likely to commit suicide—compared with people without HIV.
Pitavastatin Calcium Linked to 35% Reduced CVD Risk In People With HIV
April 14th 2023According to interim results from the REPRIEVE study, individuals with HIV who took the daily statin experienced a 35% reduced risk of major adverse cardiovascular (CVD) events, compared with those who received a placebo.
Researchers Develop Predictive Model for Kidney Function Decline in Adults With T2D
April 7th 2023Researchers developed a reliable prediction model for kidney function decline in adults with type 2 diabetes and early to moderately progressed chronic kidney disease, which was externally validated and made publicly available via a web-based application.
PLWH Who Inject Drugs More Likely to Seek Treatment Following Group Sessions
April 7th 2023Participants with HIV who inject drugs were more likely to initiate antiretroviral therapy and utilize substance use care after participating in group stigma-coping sessions, compared with those who received usual services.
Several ACA Preventive Services “Up for Grabs” Following Federal Ruling
March 31st 2023The ruling does not completely get rid of all preventive services coverage under the Affordable Care Act; it only applies to updates or new recommendations made by the US Preventative Services Task Force since March 2010.
Dr Jeremy Wigginton: Health Care Happens All the Time; Employers Need to Engage Their Population
March 27th 2023For employers, keeping members engaged with their health care is one of the key factors that leads to better outcomes, said Jeremy Wigginton, MD, vice president of health quality and innovation at Blue Cross and Blue Shield of Louisiana.
Auditory Differences Between Children With and Without HIV
March 27th 2023Similar to findings among young adults, children with HIV in Tanzania were found to have lower distortion product otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABR) wave V amplitudes, compared with children without HIV.
How Real-Time Benefit Check Can Improve Prescriber Decision-Making and Treatment Uptake
March 25th 2023Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.
What Are Some Health Plan Best Practices Surrounding Oncology Therapy Coverage?
March 25th 2023In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.
Jeffrey Casberg on Breakthrough Ophthalmic Drugs That Payers, Pharmacists Should Pay Attention to
March 25th 2023Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.